Current drug design of anti-HIV agents through the inhibition of C-C chemokine receptor type 5

Alejandro Speck-Planche, Maria Natália Dias Soeiro Cordeiro

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

14 Citas (Scopus)


Human immunodeficiency virus (HIV) is the responsible causal agent of acquired immunodeficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, allowing the entry of opportunistic infections. HIV infection in humans is considered pandemic by the World Health Organization (WHO). HIV needs to use a protein as a co-receptor to enter its target cells. Several chemokine receptors can in principle act as viral co-receptors, but the chemokine (C-C motif) receptor 5 (CCR5) is likely the most physiologically important co-receptor during natural infection. For this reason the development of new CCR5 inhibitors like anti-HIV agents, constitutes a challenge for the scientific community. The present review will focus on the current state of the design of novel anti-HIV drugs, and how the existing computer aided-drug design methodologies, have been effective in the search of new anti-HIV agents. In addition, a QSAR model based on substructural descirptors is presented as a rapid, rational and promising alternative for the discovery of anti-HIV agents through the inhibition of the CCR5.

Idioma originalInglés
Páginas (desde-hasta)238-248
Número de páginas11
PublicaciónCurrent Computer-Aided Drug Design
EstadoPublicada - dic. 2011
Publicado de forma externa


Profundice en los temas de investigación de 'Current drug design of anti-HIV agents through the inhibition of C-C chemokine receptor type 5'. En conjunto forman una huella única.

Citar esto